Flowchart illustrating the "n" values between groups throughout the study.

<p>Flowchart illustrating the "n" values between groups throughout the study.</p

Flowchart illustrating the "n" values between groups throughout the study.

<p>Flowchart illustrating the "n" values between groups throughout the study.</p

Detectable <i>ANGPTL2</i> methylation profile.

<p>Quantification of various methylation sites located in the <i>ANGPTL2</i> gene identified following a preliminary genome-wide exploratory assay. DNA samples were pooled from a small number of participants taken from all three groups. Data are mean ± SEM of a total of 16 patients from the young controls (n = 4), age-matched controls (n = 7) and post-ACS patients (n = 5).</p

Increased ANGPTL2 in post-ACS patients.

<p>Fasting ANGPTL2 levels in the plasma of patients with post-acute coronary syndrome (ACS) (n = 33) compared to age-matched (n = 20) and young (n = 20) healthy controls. Data are mean ± SEM of (n) participants, *: p<0.05 <i>vs</i> Age-matched controls (Kruskal-Wallis test).</p

Hypomethylation of CpG5 and CpG6 in post-ACS patients.

<p>Methylation percentage of the methylation sites (A) CpG1, (B) CpG2, (C) CpG3, (D) CpG5 and (E) CpG6, previously identified in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0153920#pone.0153920.g004" target="_blank">Fig 4</a>. DNA was isolated from leukocytes of post-ACS patients (n = 21), age-matched (n = 12) and young (n = 14) healthy controls. Box and whiskers plot of (n) participants, *: p<0.05 (Kruskal-Wallis test).</p

Baseline parameters of post-ACS patients.

<p>Baseline parameters of post-ACS patients.</p

Exploratory probe coordinates.

<p>Genomic localisation of probes covering ANGPTL2 CpG sites analyzed by the Infinium HumanMethylation450 exploratory assay, as provided by the manufacturer.</p

Exercise Lowers Plasma Angiopoietin-Like 2 in Men with Post-Acute Coronary Syndrome - Fig 1

<p>(<b>a</b>) Three-month aerobic exercise training lowered circulating angptl2 levels in post-acute coronary syndrome men (n = 30), but not in women (n = 10). Angptl2 levels were measured at baseline and at the end of the 3-month prevention program. Data are presented as paired individual values; *: P<0.05 <i>versus</i> baseline (Wicolxon signed rank test). (<b>b</b>) Percentage changes in angptl2 levels and in cardiopulmonary fitness (<i>V</i>O₂peak/lean body mass, ml/min/kg) between baseline and the end of the training program. Negative values correspond to a reduction in angptl2 levels; positive values correspond to an increase in angptl2 levels or in <i>V</i>O₂peak. Data are presented as mean±SEM of n values; *: P<0.05 <i>versus</i> values observed in men (Mann-Whitney test). (<b>c</b>) Negative correlation between angptl2 levels (log transformed) measured at the end of the 3-month training program and <i>V</i>O₂peak measured at baseline (in men: r = -0.462, P = 0.0116, n = 29; in women: r = -0.461, P = 0.1797, n = 10). (<b>d</b>) No correlation between hs-CRP levels (log transformed) measured at the end of the 3-month training program and <i>V</i>O₂peak measured at baseline (in men: r = -0.033, P = 0.865, n = 29; in women: r = 0.330, P = 0.352, n = 10).</p

<i>In vitro</i> methylation of <i>ANGPTL2</i> decreases promoter activity.

<p><i>In vitro</i> methylation of <i>ANGPTL2</i> target region containing CpG5 inhibited transcriptional activity, as measured by a luciferase reporter assay. Luciferase activity of methylated (M.SssI treated) and unmethylated constructs (A) containing the CpG5 site or (B) without. The assay was repeated 3 times and data are mean ± SEM. *: p<0.05 versus unmethylated (Unpaired t-test).</p

CpG5 methylation is inversely correlated with CRP concentration.

<p>Negative correlation between plasma CRP concentrations and CpG5 (p = 0.0096, r = -0.395, n = 42) and CpG6 (p = 0.1731, r = -0.214, n = 42) methylation in all participants (n = 14 young healthy controls, n = 9 age-matched healthy controls, n = 19 post-ACS patients).</p